The Unicellular Reversion Hypothesis of Cancer
Rethinking Cancer: What a Protein’s History and Ammonia Signaling Reveal About the Disease.
There is a protein sitting in the membrane of almost every cell in your body that is, structurally speaking, virtually identical to a protein found in the first bacteria that ever lived on Earth. It has been doing essentially the same job, to move ammonia across a lipid bilayer, for roughly 3.8 billion years. In all that time, evolution never replaced it. Never found a better solution. Never even significantly redesigned the core mechanism.
What evolution did do, at some point around 600 to 800 million years ago, was flip the direction.
That directional flip, from pulling ammonia in to pushing ammonia out, is one of the most consequential molecular events in the history of multicellular life. And there is growing evidence that in cancer, under conditions of chronic oxygen starvation, that flip reverses. Not completely, not cleanly, but functionally: the cancer cell activates highly conserved, primitive genetic pathways that predated the evolution of its host organism.
The Protein That Evolution Could Not Improve Upon
The Amt/Mep/Rh superfamily (Ammonium Transporters, Methylammonium Permeases, and Rhesus glycoproteins) is ubiquitous across all three domains of life. Bacteria use AmtB. Fungi and plants use Mep transporters. Animals express Rhesus glycoproteins, of which RHCG (encoded by SLC42A3) is the primary ammonia-exporting isoform in the kidney collecting duct, intestine, and multiple other tissues under metabolic stress.
These proteins are not merely homologous in a loose, sequence-similarity sense. Their three-dimensional pore architecture, the actual molecular geometry of the channel through which ammonia passes, is structurally conserved across the full phylogenetic span, from Escherichia coli AmtB to human RHCG. X-ray crystallography has confirmed it. The same protein fold, the same arrangement of transmembrane helices, the same critical residues in the same positions preserved across a timespan that dwarfs the existence of complex animals by orders of magnitude.
The reason evolution could not simply discard this architecture and build something new lies in what is arguably the most elegant unsolved engineering problem in early cell biology.
The Potassium Mimicry Problem
Ammonium (NH₄⁺) and potassium (K⁺) are, from the perspective of a membrane channel, nearly indistinguishable. Their ionic radii are almost identical. Their charge is the same. Any non-specific cation pore that permits NH₄⁺ transit will also permit K⁺ to flood through destroying the membrane potential, collapsing the electrochemical gradient, and killing the cell.
The Amt/Mep/Rh solution, evolved once and never surpassed, is a four-step mechanism built around a structure called the Twin-Histidine motif — two precisely positioned histidine residues that protrude into the narrowest section of the pore lumen.
The Four-Step Twin-Histidine Mechanism
- Recruitment Vestibule. The charged ammonium ion (NH₄⁺) docks at the outer mouth of the channel, held by acidic residues. Potassium (K⁺) can also dock here — this is not yet the filter.
- Proton Strip: The Filter. The two histidine residues act as a chemical catalytic filter. They strip a proton (H⁺) from the NH₄⁺, converting it into neutral ammonia gas (NH₃). Potassium cannot be deprotonated. It is flatly rejected here.
- Hydrophobic Single-File Transit. The neutral NH₃ gas slips through a 12-Ångström hydrophobic channel core. The hydrophobic lining repels water and ions so only the neutral gas species can pass.
- Exit and Reassociation. On the far side of the membrane, NH₃ picks up a free proton and becomes NH₄⁺ again.
What this mechanism achieves is the selective, high-fidelity transport of one chemically indistinguishable species over another, something no simple ion channel architecture could accomplish. The Twin-Histidine deprotonation step is the lock that no other molecule can pick. This is why the Amt/Mep/Rh pore has been conserved for nearly four billion years: the chemistry that justifies its existence has not changed.
The Flip: From Nutrient to Poison and Back Again
→ Unicellular World (~3.8 Bya)
INFUSION VALVE
- Amt/Mep channels scavenge nitrogen as NH4+ inward as a biosynthetic resource.
- Ammonia = nutrient.
- Used by bacteria, yeast, and algae for 3 billion years.
← Multicellular Transition (~600 Mya)
EFFUSION VALVE
- Internal ammonia destroys electrochemical gradients and impairs mitochondria.
- Ammonia = toxin.
- Evolution flips RHCG to expel NH₃ into urine, gills, and sweat.
Ortiz-Barrientos and colleagues formalised this evolutionary flip in a 2021 paper in mBio, providing the comparative genomic framework showing how the same structurally conserved protein family underwent functional reversal across the transition from unicellular to multicellular life.
Under chronic hypoxia, HIF-1α (hypoxia-inducible factor 1-alpha) stabilises and drives a transcriptional programme that restructures the cell's entire metabolic logic — upregulating glycolysis, blocking mitochondrial entry of pyruvate, and directly upregulating RHCG as a pressure-relief valve for the ammonia and protons that accumulate when oxidative phosphorylation collapses. The hypoxia-RHCG axis represents the direct intersection of evolutionary programming and modern tumor biology. In acute hypoxia, it is a transient survival response. In the chronic hypoxia of a solid tumour, it becomes a locked, epigenetically heritable state. That said, the upregulation of RHCG under hypoxic conditions is not universal; in hypoxic esophageal, cervical, and head and neck squamous cell carcinomas (HNSCC), RHCG is silenced via promoter hypermethylation. But whether RHCG is upregulated or silenced in cancer, it is best-fitted to context, and both outcomes disrupt the tissue's normal handling of ammonia.
The cell is no longer in emergency mode. It has structurally committed to a different operating system.
Ammonia in the Tumour: From Byproduct to Signal
The canonical framing of ammonia in the tumour microenvironment describes it as toxic waste that cancer cells must manage to avoid self-poisoning. This framing is incomplete. A growing body of evidence, much of it published within the last two to three years, supports a substantially more active role: ammonia in the TME is a signalling molecule, systematically exploited by cancer cells to orchestrate the conditions that favour their survival.
The primary ammonia source is glutaminolysis. Cancer cells catabolise glutamine at rates far exceeding normal tissue: first to glutamate (via glutaminase, releasing NH₃), then to alpha-ketoglutarate (via glutamate dehydrogenase, releasing a second NH₃). Under normal physiology, this ammonia would be cleared by the urea cycle. In most solid tumours, the urea cycle is systematically silenced: CPS1 is suppressed by promoter DNA methylation, OTC and ARG1 are downregulated at the protein level in tumour tissue, and ASS1 is epigenetically silenced across multiple cancer types. The cancer cell has not merely lost a metabolic function — it has abdicated from the organism's shared nitrogen management infrastructure.
What accumulates as a result is ammonia, and what ammonia does next is where this story becomes most interesting.
Five Ways Ammonia Architects the Tumour Microenvironment
mTORC1 Activation & Proliferation
At moderate concentrations, ammonia activates mTORC1 by mimicking nitrogen sufficiency — driving protein synthesis and cell proliferation. This is the same TOR-pathway logic used by yeast and bacteria to couple nitrogen availability to growth rate. The cancer cell is reading ammonia as a nutrient signal, exactly as its unicellular ancestors did.
mTOR-Independent Autophagy
Ammonia also induces autophagy through a DRD3/VPS34-dependent pathway, independent of mTOR inhibition (Eng et al., 2010). Autophagy, cellular self-recycling under nutrient stress, is a classical unicellular survival strategy. Here, the same molecule that signals growth also primes the cell's survival machinery for when conditions worsen.
pH Alkalinisation
As neutral NH₃ gas (~2.2% of total ammonia at physiological pH), ammonia traverses membranes freely, alkalinising lysosomes and disrupting proteolysis. This raises extracellular pH, increasing tumour invasiveness and protecting cancer cells from acid-sensitive immune killing mechanisms.
The SAM-DNMT Epigenetic Loop
Processing ammonia depletes S-adenosylmethionine (SAM) — the universal methyl donor for DNA methylation. SAM depletion causes genome-wide hypomethylation, unsilencing the ancient unicellular gene programmes that methylation was suppressing. Ammonia erodes its own epigenetic brakes. The reversion deepens and self-reinforces.
Cancer Stem Cell Niche Maintenance
The ammonia-enriched, alkaline, epigenetically plastic TME subregion is where cancer stem cells (CSCs) — the most dedifferentiated, most therapy-resistant subpopulation — preferentially reside. CSCs are, by definition, the most ancient-gene-expressing cells in the tumour. The unicellular survival programme creates the optimal conditions for its own most extreme expression. This is why targeting CSCs through conventional cytotoxic approaches has been so difficult: you are not fighting a cell that has gained a new capability. You are fighting a cell that has reverted to an ancient one, in the environment it evolved to survive.
Putting It Together: One Molecule, One Direction
| Ammonia Action | Mechanism | Net Effect for Tumour |
|---|---|---|
| mTORC1 activation | Amino acid sensor mimicry → anabolic signalling | Increased proliferation |
| Autophagy induction | DRD3/VPS34 pathway (mTOR-independent) | Survival under nutrient stress |
| Lysosomal alkalinisation | NH₃ gas trapping → raised compartment pH | Impaired proteolysis; invasion advantage |
| SAM depletion | One-carbon metabolism burden → DNA hypomethylation | Derepression of ancient gene programmes |
| CSC niche creation | pH + epigenetic plasticity + mTOR signalling | Maintenance of therapy-resistant subpopulation |
| Immune suppression | Perforin degradation; T-cell exhaustion; Treg empowerment | Elimination of immune surveillance (covered in Part III) |
A Convergent Picture
What emerges from placing the evolutionary history of RHCG alongside the signalling biology of ammonia in the same frame is more coherent than either story alone suggests.
The cancer cell under chronic hypoxia activates HIF-1α, which drives the Warburg Effect and upregulates RHCG as a pressure valve. RHCG extrudes ammonia and protons, buying the cell time. But the cellular context has changed: the cell has silenced its own urea cycle, severing its connection to the organism's shared detoxification system. Ammonia accumulates locally. It activates mTOR. It induces autophagy. It alkalinises lysosomes. It depletes SAM, eroding the epigenetic suppressors of the ancient programme. And it systematically disables the immune cells that would otherwise recognise and eliminate the cell that created it.
In a unicellular organism, this is exactly what survival looks like: acquire nitrogen, signal growth, recycle internal resources, alkalinise the local environment, and suppress competing organisms. The cancer cell is not doing something new. It is doing something 3.8 billion years old, in a body that evolved over hundreds of millions of years to prevent precisely this.
Understanding that the molecular tools involved (RHCG, mTOR, glutamate dehydrogenase, the urea cycle, the epigenetic machinery) are not cancer-specific mutations but conserved, ancient, repurposed systems changes how we should think about targeting them. You are not looking for a tumour-specific vulnerability that appeared de novo in a mutant cell. You are pinpointing the genetic intersection of single-celled and multicellular evolutionary frameworks to understand how to tip the balance back toward multicellular control.
%20(3).png)
%20(3).png)
